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Abstract 
An improved, convenient synthesis of 3-deoxy-D-xy/o-hexose (3-deoxy-D-galactose) has been developed, and the chemical synthesis of 
a novel monosaccharide rivative, methyl (methyl 4-chloro-4-deoxy-fl-D-galactopyranosid)uronate (compound 10), is described. Using 
primary hepatocytes in culture, each was used to explore its effect on glycosaminoglycan (GAG) synthesis. In the absence of analogues 
hepatocytes synthesize primarily (92-95%) heparan sulphate. At 1 mM, 3-deoxy-D-galactose had little observable ffect on either liver 
cell GAG or protein synthesis. At 10 mM and 20 mM, 3-deoxy-D-galactose r duced [3H]glucosamine and 35SO4 incorporation i to 
hepatocyte cellular GAGs to, respectively, 75% and 60% of the control cells. This inhibition of GAG synthesis occurred without any 
effect on hepatocyte protein synthesis, indicating that 3-deoxy-D-galactose's effect on GAG synthesis is not mediated through an 
inhibition of proteoglycan core protein synthesis. Furthermore, GAGs in the presence of 20 mM of the analogue were significantly 
reduced in size, 17 kDa vs. 66 kDa in untreated cells. These results reflect either impaired cellular GAG chain elongation, and/or altered 
GAG chain degradation. Compound 10 exhibited a concentration-dependent inhibition of both hepatocyte cellular GAG and protein 
synthesis. At concentrations of 5, 10 and 20 mM, compound 10 inhibited GAG and protein synthesis by 20, 65 and 90%, respectively. 
Exogenous uridine was able to restore partially the inhibition of protein synthesis, but was unable to reverse the effect of compound 10 on 
GAG synthesis. These results show that part of the effect of compound 10 on GAG synthesis is not mediated by an inhibition of 
proteoglycan core protein synthesis. GAGs in the presence of compound 10 are half as large as those in the absence of this compound (33 
and 66 kDa, respectively). These results again may reflect either impaired cellular GAG chain elongation and/or altered GAG chain 
degradation. Potential metabolic routes for each analogue's effect are presented. 
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I. Introduction 
Recent investigations into the pathogenesis of metas- 
tases in cancer [1], arthritis [2], and of amyloid in 
Alzheimer's disease and adult onset diabetes [3,4], have 
indicated the growing importance of the role which the 
extracellular matrix may play in the development of major 
human diseases. 
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Glycosaminoglycans (GAGs) are significant structural 
components of the extracellular matrix [5-7]. Analogues of 
GAG building blocks are limited in number. With the 
exception of several well established analogues of D-xylose 
[5,8-14], there are relatively few such experimental 
metabolic tools available. Increased availability, and num- 
ber, of these analogues could provide tools which perturb 
GAG metabolism and in so doing shed light on the role of 
GAGs in the above mentioned isorders. Such analogues 
may also provide clues to the development of novel thera- 
peutic agents. These therapeutic agents may be particularly 
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useful in clinical situations in which an excess of produc- 
tion of GAGs, proteoglycans, or extracellular matrix plays 
a significant role in the genesis of these disorders. Clinical 
examples include exuberant scar tissue as in keloid forma- 
tion [15], overgrowth of synovial connective tissue in 
rheumatoid arthritis [16], glomerular sclerosis in glomer- 
ulonephritis [17,18], and the development of amyloid de- 
posits in a variety of different clinical disorders, the most 
common of which is Alzheimer's disease [3]. 
In proteoglycans, other than keratan sulphate, GAGs are 
linked by a specific tetrasaccharide (D-glucuronic acid-D- 
galactose-D-galactose-D-xylose) t  its protein core by a 
xylose-serine bond [19]. The D-glucuronic acid unit is 
coupled to the D-galactose in a /3-(1 ~ 3) linkage, as are 
the two D-galactose units [19]. The goal in the present 
study was to develop monosaccharide rivatives which, in 
an appropriate test system, would affect GAG synthesis, 
but not by interfering with cell protein synthesis. The 
nature of these compounds was such as to provide, either 
(1) the potential to be incorporated into the growing GAG 
chain and in so doing prevent further elongation of the 
polysaccharide, or (2) the potential to serve as an inhibitor 
of naturally occurring sugar metabolites so as to interfere 
with the elongation of the polysaccharide. Because of the 
central structural role of o-galactose in the GAG-protein 
linkage region and the involvement of /3-(1 ~ 3) bonds, 
we chose to synthesize 3-deoxy-o-xylo-hexose (3-deoxy- 
D-galactose) (compound 6, see Fig. 1) and examine its 
effects on GAG synthesis using hepatocytes in tissue 
culture. Synthetic routes to 3-deoxy-D-galactose have been 
reported [20-26]. The method developed in the present 
work starting with D-glucose is a facile, convenient, and 
high-yielding synthesis. 
Since o-glucuronic acid (7) plays a central role in the 
structure of several different GAGs, a structural analogue 
of o-glucuronate was developed with emphasis being di- 
rected at the hydroxyl group at C-4, as this represents he 
growing end of the nascent GAG chain. We describe here 
the synthesis of a novel monosaccharide rivative, namely 
methy l  (methy l  4 -ch lo ro -4 -deox  y- /3-D-  
galactopyranosid)uronate (compound 10, see Fig. 2), and 
its effect on hepatocyte GAG synthesis. 
The starting material for the synthesis of compound 10 
was commercially available D-glucofuranurono-6,3-1actone 
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Fig. 1. Synthesis of 3-deoxy-D-xylo-hexose (3-deoxy-D-galactose). 
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Fig. 2. Structure of I>glucuronic acid (7) and synthesis of methyl (methyl 
4-chloro-4-deoxy-Ctq>galactopyranosid)uronate (10). 
(8). The route involved a base-catalyzed sterification [27] 
to afford the methyl ester 9, which was converted then into 
the 4-chloro derivative 10 by the sulphuryl chloride 
methodology [28]. 
2.2. Synthesis of 3-deoxy-o-galactose (see Fig. 1) 
1,2 : 5, 6-D i-O-isop rop y lidene-a-D-e rythro-hex-3-en- 
ofuranose (Compound 4) 
To a solution of 1,2:5,6-di-O-isopropylidene-a-D-gluco- 
furanose (2, 3.42 g, 13.2 mmol; prepared by treatment of 
D-glucose (1) with acetone and sulphuric acid [29]) in dry 
dichloromethane (100 ml) at 0°C was added dry pyridine 
(2.9 ml, 36 mmol) with stirring, under nitrogen, followed 
by trifluoromethanesulphonic anhydride (4.7 ml, 28 mmol). 
The reaction mixture was stirred at 0°C for 30 rain and 
then at room temperature for 30 min, and then was washed 
sequentially with ice-cold 3% hydrochloric acid (10 ml) 
and water (20 ml), dried (MgSO4), and evaporated to 
dryness to give a sample of 1,2:5,6-di-O-isopropylidene-3- 
O-trifluoromethanesulphonyl-a-D-glucofuranose (3, 4.09 g, 
98.8%) which migrated as a single component in TLC on 
silica-gel (ethyl acetate/toluene (1:4, v/v)). 
To a solution of a sample of 3 (4.7 g, 12 mmol; 
prepared as described above) in acetonitrile (40 ml) was 
added a 1 M solution (20 mi) of tetra-n-butylammonium 
fluoride in tetrahydrofuran. The reaction mixture was kept 
at room temperature overnight and then heated at reflux 
temperature for 3 h. The solvent was removed by evapora- 
tion, and a solution of the residue in dichloromethane (200 
ml) was washed with water (2 × 30 ml), dried (MgSO4), 
and evaporated. The residue was purified by column chro- 
matography on silica-gel using ethyl acetate/toluene (1:10, 
v/v) as eluent to give compound 4 (2.48 g, 85.5%) in 
crystalline form, m.p. 47-48°C, lit. (24)m.p. 50 ° C; tH- 
NMR (CDC13): 6 1.30 (s, 3 H, Me), 1.38 (s, 3 H, Me), 
1.41 (s, 6 H, 2 Me), 3.93 (dd, 1 H, J6.5 5.0, J6,6 9.0 Hz, 
H-6), 4.09 (dd, 1 H, J6,5 7.0, J6.6 9.0 Hz, H-6), 4.53 (ddd, 
1 H, J5.6 5.0, "]5,6 7.0, J5.3 2.0 Hz, H-5), 5.19 (dd, 1 H, 
J3.2 1.0, J3,5 2.0 Hz, H-3), 5.25 (ddd, I H, J2.1 5.0, J2,3 
1.0, J2,5 1.0 Hz, H-2), 6.03 (d, 1 H, J1.2 5.0 Hz, H-l). 
2. Materials and methods 
2.1. General methods 
Melting points were determined on a Fischer-Johns 
apparatus and are uncorrected. Optical rotations were mea- 
sured with a Perkin-Elmer model 241 automatic polarime- 
ter for solutions in a 0.1-din cell. t H-NMR spectra were 
recorded with a Bruker AM-400 (400 MHz) spectrometer, 
with tetramethylsilane (M 4Si) as the internal standard, for 
solutions in CDCI3, unless otherwise stated. 13C-NMR 
spectra were recorded at 100.6 MHz; chemical shifts of all 
of the signals are given in ppm downfield from the signal 
of Me4Si. 
Column chromatography was performed on silica-gel 
60 (70-230 mesh, Merck). Solvents were evaporated un- 
der reduced pressure below 40 ° C. 
3-Deoxy- l,2:5,6-di-O-isopropylidene-a-D-galactofuranose 
(Compound 5) 
A solution of compound 4 (2.42 g, 10 mmol) in methanol 
(60 ml) was subjected to a hydrogen atmosphere (45 
p.s.i.g.) in the presence of W-4 Raney nickel catalyst 
(approx. 2 g) for 2.5 h. The catalyst was removed by 
filtration, and the filtrate was evaporated to dryness. The 
residue was purified by column chromatography on silica- 
gel using ethyl acetate/toluene (l:10, v/v) as eluent to 
give compound 5 (2.31 g, 95%) in crystalline form, m.p. 
78-79°C, lit. (24) m.p. 81°C; 1H-NMR (CDCl3): 6 1.26 
(s, 3 H, Me), 1.30 (s, 3 H, Me), 1.38 (s, 3 H, Me), 1.51 (s, 
3 H, Me), 1.75 (ddd, 1 H, J3,3 14.0, J3.2 1.0, J3,4 4.0 Hz, 
H-3), 2.16 (ddd, 1 H, J3.3 14.0, J3,2 6.0, J3.4 8.0 Hz, H-3), 
3.55 (dd, 1 H, -/6.6 8.0, J6,5 6.0 Hz, H-6), 4.00 (dd, 1 H, 
J6.6 8.0, J6,5 6.0 Hz, H-6), 4.06 (ddd, l H, J4.3 8.0, J4~3 
4.0, J4,5 4.0 Hz, H-4), 4.39 (ddd, 1 H, J5.4 4.0, .15.6 .0, 
-/5,6 6.0 Hz, H-5), 4.68 (ddd, 1 H, J2,1 4.0, J2.3 1.0, J2,3 
6.0 Hz, H-2), 5.76 (d, I H, JL2 4.0 Hz, H-l). 
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3-Deoxy-D-xylo-hexose (3-Deoxy-o-galactose, Compound 
6) 
Compound 5 (2.1 g, 8.6 mmol) was heated at reflux 
temperature in 0.4 N sulphuric acid for 90 min. The 
reaction mixture was cooled to room temperature, neutral- 
ized with barium carbonate, and filtered; the residue was 
washed with water (40 ml). The combined filtrate and 
washing were stirred for 5 min in the presence of Amber- 
lite IR-120 (H ÷) resin (5 ml). The resin was removed by 
filtration, and the filtrate was evaporated to dryness; the 
residue was dissolved in 100% ethanol (20 ml) and the 
solution was evaporated to dryness. The residue was puri- 
fied by column chromatography on silica-gel using chloro- 
form/ethanol (7:3, v /v)  as eluent to give compound 6 
(1.1 g, 78%) as a syrup, [a]~ 5+ 5.1 ° (c 2.34, water) lit. 
(24) [a]  2° + 6.5 ° (c 2.07, water), lit. (26) [a]  22 + 5.1 ° (c 
1, water). The ~H-NMR data were in agreement with those 
reported by Angyal and Pickles [30]. ~H-NMR spec- 
troscopy revealed that the sample of 3-deoxy-D-galactose 
exists in aqueous olution at room temperature as a mix- 
ture of 27.7% of the a-pyranose and a-furanose forms, 
53.7% of the /3-pyranose form, and 18.6% of the /3-fur- 
anose form; 1H-NMR (D20; 2,2-dimethyl-2-silapentane- 
5-sulphonate (DSS)): 6 4.55 (JJ,2 8.0 Hz, H-1 of /3- 
pyranose), 5.18 (Ji.2 4.0 Hz, H-1 of a-pyranose and 
a-furanose), 5.25 (Ji.2 1.0 Hz, H-1 of /3-furanose). 
The method described for the synthesis of 3-deoxy-D- 
galactose is a modification of the route reported by others 
[22,24]. In this earlier work compound 2 was converted 
into its 3-O-p-tolylsulphonyl derivative which was trans- 
formed into the unsaturated derivative 4 by the use of a 
solid soda lime catalyst. This procedure is considerably 
less convenient than the one developed in the present work 
and, in our hands and as reported by others [22,24], is 
lower-yielding. 
2.3. Synthesis of methyl (methyl 4-chloro-4-deoxy-t~-D- 
galactopyranosid)uronate (Compound 10) (see Fig. 2) 
o-Glucofuranurono-6,3-1actone (8, 20.5 g; purchased 
from the Aldrich Chemical) was suspended in a solution 
(100 ml) of 0.5% sodium in methanol. The reaction mix- 
ture was stirred at room temperature for 1.5 h, and then 
concentrated to an amorphous residue (28.3 g) which 
contained methyl D-glucopyranuronate (9).
To a solution of the material obtained above in pyridine 
(80 ml) was added chloroform (70 ml). The mixture was 
cooled to -78  ° C, and sulphuryl chloride (60 ml) was 
added slowly with vigorous stirring over a period of 
approx. 1 h. Stirring was continued at -78°C for 1.5 h 
and then at room temperature for 24 h. Cooled diethyl 
ether (200 ml) was added, and the precipitate was removed 
by filtration through Celite. The ether layer was washed 
sequentially with cooled water (3 × 50 ml), a saturated 
aqueous solution (50 ml) of sodium hydrogencarbonate, 
and cooled water (50 ml), dried (MgSO4), and concen- 
trated to a brown syrup. To a solution of the syrup in 
methanol (150 ml) was added sodium hydrogencarbonate 
(50 g) and then sodium iodide (approx. 200 mg) until the 
liberation of iodine was no longer observed. The mixture 
was stirred at room temperature overnight and then fil- 
tered. The filtrate was concentrated to a residue which was 
fractionated by flash chromatography on silica-gel (230- 
400 mesh) using ethyl acetate as eluent o give the prepon- 
derant component as a syrup (7.5 g). Crystallization from 
ethyl acetate and recrystallization from methanol-ethyl ac- 
etate-n-hexane afforded compound 10 as a colorless crys- 
talline product (4.9 g), m.p. 153.5-154°C; [a]  2° -33.0 ° 
(c 1.0, ethanol); 13C-NMR (D20; 1,4-dioxane): 6 55.5 
(ester OMe), 58.2 (OMe at C-l), 64.2 (C-4), 72.2, 73.5 
and 75.3 (C-5, C-3 and C-2), 106.2 (C-l), 171.3 (C-6). 
(Found: C, 39.99; H, 5.30; C1, 14.88; C8H1306C1 requires 
C, 39.93; H, 5.44; C1, 14.73). 
In a separate xperiment, in addition to the isolation of 
compound 10, the presence of its a-anomer was detected 
and methyl 5-chloro-5-deoxy-a-L-idofuranosidurono-6,3- 
lactone [31,32] was isolated in crystalline form in 18% 
yield (based on compound 8); the formation of the L-ido 
derivative is attributable to the presence of starting mate- 
rial (compound 8) in the product from the base-catalyzed 
esterification reaction. 
2.4. Biological evaluation 
Materials 
D-(1,6- 3 H 2)-Glucosamine-HC1 (68.5 Ci/mmol) and L- 
(4,5- 3 H 2)leucine (53 Ci/mmol) were purchased from New 
England Nuclear. Na35SO4 (43 Ci/mg) was purchased 
from ICN Biomedicals, Laboratory chemicals of reagent 
grade were obtained from Sigma Chemical, Fisher Scien- 
tific, or BDH Chemicals. Williams' Medium E with L- 
glutamine, Ultroser G, and antibiotic-antimycotic mixtures 
were supplied by Gibco. Fibronectin, coUagenase, papain, 
gel filtration standards, and the GAG reference standards 
as sodium salts were purchased from Sigma Chemical. 
Alcian blue was obtained from Fisher Scientific. D-Galac- 
tose was obtained from BDH Chemicals. D-Glucuronate 
was obtained from Sigma Chemical. Sephacryl S-300 su- 
perfine was purchased from Pharmacia Fine Chemicals. 
Cellulose polyacetate (Sepraphore III) electrophoresis trips 
were purchased from Gelman Sciences. 
2.5. Hepatocyte isolation and cell culture 
Hepatocytes were obtained from 6-8 week old, female 
Swiss White mice (Charles River Canada, St. Constant, 
Quebec) by the procedure described previously [33,34]. 
Briefly, the liver was perfused with 50 ml of 0.01 M 
Hepes buffer (pH 7.4) containing 0.5 mM EGTA, followed 
by 50 ml of a collagenase type-IV solution (0.5 mg/ml) in 
0.1 M Hepes (pH 7.6). The liver was removed and the 
hepatocytes separated from the capsule by gentle teasing. 
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The pooled cells were centrifuged at 200 r.p.m, for 5 min, 
and washed once with fresh medium. After resuspension i  
20 ml of Williams' Medium E and filtration through a 
nylon membrane, the cells were exposed to Trypan Blue 
and counting on a hemocytometer o determine the viabil- 
ity and cell number. The viability was usually greater than 
85%. The cells were plated in triplicate on fibronectin- 
coated tissue culture dishes (Falcon 35 × 10 mm) at a 
density of 1-2- 10 6 cells per plate. They were incubated 
in 2 ml of Williams' Medium E containing 1% Ultroser G 
and 1% antibiotic-antimycotic mixtures. After 2 h, the 
non-adherent cells were removed, and the attached cells 
were fed with fresh plating medium for a 24-h period. The 
cells were then provided with fresh medium containing the 
necessary isotopes and/or monosaccharide rivative. For 
GAG labelling, [3H]glucosamine (2 /.~Ci/ml) and Na~SSO4 
(4 /zCi/ml) were included in the medium. For experi- 
ments monitoring protein synthesis, the cells were incu- 
bated with [3H]leucine (0.5 ~Ci/ml). The labelled cellular 
GAGs, or total protein, were harvested 24 h later. 
In a series of preliminary experiments the effects of 
various extracellular matrices, cell density, and labelling 
periods were evaluated to determine optimum culture la- 
belling conditions. 
For the evaluation of the effect of uridine, uridine was 
incorporated into the medium at the time of the addition of 
the radiolabelled precursors and was tested at concentra- 
tions ranging from 0.1 /zM to 1.0 mM. 
2.6. Glycosaminoglycan isolation 
After the 24-h labelling period, the medium was sepa- 
rated from the cells and the cells were solubilized in 4 M 
guanidine-HC1, 2% Triton X-100 in 0.05 M acetate buffer 
(pH 6.0). A GAG carrier (1 mg/ml each of chrondroitin 
sulphate, hyaluronan, and heparin sulphate) was added to 
all of the samples. The isolation of the radioactive GAGs 
was based on the cetylpyridinium chloride (CPC) precipi- 
tation technique described by Hronowski et al. [35]. Briefly, 
media and cell fractions were each subjected to papain 
digestion and the GAGs precipitated as sodium salts by 
CPC. After lyophilization the samples were dissolved in a 
known volume of water for analysis. Media GAGs were 
analysed only during preliminary experiments. Cellular 
GAGs served as the assay material for the effects of the 
sugar analogues. 
2.7. Electrophoretic separation and measurement of ra- 
dioactive [ 3H]glucosamine and 35S04 incorporation into 
g lyc o samino g lyc ans 
The isolated GAGs were separated by cellulose acetate 
electrophoresis and stained with Alcian Blue [36]. Elec- 
trophoresis was carried out for 1.5 h at 10 mA per eight 
cellulose acetate strips. The strips were stained for 5-10 
min and rinsed in destaining solution for three 5-min 
intervals. The stained bands and the area between the 
stained bands were cut from the air-dried cellulose acetate 
strips and immersed in 5 ml of scintillation solution (Uni- 
versol ES-ICN). A Beckman LS-1701 liquid scintillation 
spectrophotometer wasused to measure the radioactivity. 
2.8. Characterization of hepatocyte glycosaminoglycans 
GAGs synthesized by hepatocytes were partially charac- 
terized by their sensitivity to depolymerization with nitrous 
acid as described by Shivley and Conrad [37], and their 
electrophoretic mobility as measured against commercial 
standards. The GAG reference standards chosen included 
hyaluronan from human umbilical cord, heparan sulphate 
from bovine kidney, chondroitin sulphate from shark carti- 
lage, and heparin from porcine intestinal mucosa. Of the 
three cell types analyzed, namely macrophages, lympho- 
cytes and hepatocytes, hepatocytes made predominantly 
heparan sulphate, and this cell type was chosen for the 
culture system to assess the effects of the monosaccharide 
analogues. 
2.9. Cell-culture protein synthesis 
Total cell protein synthesis was determined by measur- 
ing [3H]leucine incorporation. After the cells had been 
incubated in labelling medium for the specified period of 
time, the culture medium was removed, and the cell frac- 
tions were solubilized by treatment with 1% SDS and 
combined with the medium. The proteins were precipitated 
by the addition of 3 ml of 10% trichloroacetic a id (TCA) 
containing 10 mg/ml DL-leucine. The samples were heated 
to 90 ° C for 30 min to destroy leucine tRNA and cooled at 
4 ° C for 30 min. Using a Millipore 1225 sampling mani- 
fold, the samples were filtered through glass microfibre 
filters (Whatman 934-AH), and washed three times with 5 
ml of cold 5% TCA containing 10 mg/ml DL-leucine and 
once with 3 ml of ethanol. The filters were air-dried and 
immersed in 5 ml of scintillation solution, and the radioac- 
tivity was measured. Nonspecific binding of [3H]leucine 
was not more than 5% of the total incorporated radioactiv- 
ity. 
2.10. Determination of glycosaminoglycan size 
The size of the GAG chains made in the absence or 
presence of the analogues (20 mM) was investigated using 
GAGs synthesized in the presence of [3H]glucosamine and 
Na35SO4 . The labelled GAGs were isolated from the cell 
fraction as described above. Gel filtration chromatography 
on a Sephacryl S-300 column (0.7 cm × 100 cm) was 
performed by eluting with 4 M guanidine-HCl, 0.05 M 
sodium acetate, 0.5% Chaps (pH 6.0), with a flow rate of 
4.3 ml/h. The column was calibrated by monitoring the 
elution volumes of the following proteins: bovine thyro- 
globulin, 330 kDa; E. coli /3-galactosidase, 116 kDa; 
42 Susha S. Thomas et al. / Biochimica et Biophysica Acta 1272 (1995) 37-48 
bovine serum albumin, 66 kDa; bovine pancreatic a- 
chymotrypsinogen A, 25 kDa; and horse heart myoglobin, 
17 kDa. The void volume and total volume were deter- 
mined using Blue dextran and Na 35 SO 4, respectively. The 
K,,. of the above mentioned standards were 0.03, 0.15, 
0.26, 0.38, and 0.44, respectively. 
Radioactively labelled GAGs were applied to the col- 
umn and 0.58-ml fractions collected. Aliquots of each 
fraction were analyzed for 3H and 35S by liquid scintilla- 
tion spectroscopy. The resulting chromotographic profiles 
of GAGs synthesized in the absence or presence of 
monosaccharide rivatives were compared. 
3. Results 
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3.1. Preliminary experiments 24 
In preliminary experiments several cell types were ex- 
amined for their usefulness in providing a culture system 
which synthesized primari ly heparan sulphate. 
Macrophages, lymphocytes, and hepatocytes were evalu- 
ated, and hepatocytes proved to be the most appropriate 
cell type for the work being planned. Of the total medium 
and cellular GAGs synthesized by hepatocytes, 92-95% 
were nitrous acid-sensitive. Therefore, inhibition of GAG 
synthesis significantly greater than 5-8% must reflect 
significant inhibition in heparan sulphate synthesis. 
Hepatocytes from mature animals, which do not divide 
in culture, incorporated [3H]glucosamine and 35504 lin- 
early into total GAGs for at least 96 h. Cellular GAG 
radioactivity, as [3H]glucosamine and 35504 incorporation, 
increased linearly for approx. 24 h and then plateaued, 
reflecting the balance between cell GAG synthesis and 
secretion or loss by degradation. Measurement of isotope 
incorporation into cell GAGs after 24 h of labelling is 
therefore a measure of net cellular GAG synthesis. The 
media supplement, Ultroser G, a synthetic serum substi- 
tute, proved to be much more effective than fetal calf 
serum. Ultroser G led to a 67% stimulation of [3H]gluco- 
samine incorporation and a 40% stimulation of 35504 
incorporation into cellular heparan sulphate, when com- 
pared to fetal calf serum. A comparison was also made of 
the influence of extracellular matrix proteins on hepatocyte 
GAG synthesis. These included collagen, fibronectin, and 
laminin. Fibronectin resulted in a 10% stimulation of 
radiolabel incorporation. Furthermore, the cells appeared 
healthier by morphological criteria. Hepatocyte cell density 
also affected GAG precursor incorporation, but hepatocyte 
proliferation in culture does not occur with cells from 
mature animals so that changing density during culture 
was not a problem. GAG synthesis increased in a linear 
fashion to approx. 2 .10  a cells per culture. Beyond this 
cellular density the incorporation of [3H]glucosamine and 
35 SO 4 increased but in a non-linear fashion. 
On the basis of the above results the final conditions for 
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Fig. 3. Effects of increasing concentration of o-galactose on hepatocyte 
cellular GAG and total protein synthesis. Hepatocyte cultures were 
incubated with [3H]glucosamine/35SO 4, or [3H]leucine, for 24 h in the 
absence (control) or presence of o-galactose at 1, 10 and 20 mM. The 
radioactivity incorporated into cell GAGs, or protein, are illustrated in
panels A and B, respectively. The values represent the mean_+S.D, of
triplicate cultures. 
the assay system were as follows: hepatoctyes plated on 
fibronectin, at a density of 1-2- l0 6 cells per plate, were 
allowed to establish themselves for 24 h, following which 
time net GAG synthesis was monitored over the next 24 h. 
Cellular GAGs were then isolated for analysis. 
3.2. The effect of increasing o-galactose or o-glucuronic 
acid concentration on hepatocyte GAG synthesis 
The addition of D-galactose at concentrations of 1, 10 
and 20 mM did not have any significant effect on hepato- 
cyte GAG synthesis. Fig. 3A demonstrates the incorpora- 
tion of [3H]glucosamine and 35504 by hepatocytes in the 
presence and absence of additional media o-galactose. 
These data indicate that galactose added at the chosen 
concentrations did not alter the cellular glucosamine pool 
and change the [3H]glucosamine specific activity. Further, 
there was no significant change in the incorporation of 
[3H]leucine into protein after the addition of galactose at 
the various concentrations indicated (Fig. 3B). Similarly 
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the addition of D-glucuronic acid at concentrations of 1, 10 
and 20 mM did not have any significant effect on hepato- 
cyte GAG or protein synthesis (Fig. 4A and 4B, respec- 
tively). These results serve as a standard of reference for 
the monosaccharide rivatives, and also indicate that any 
effect that the corresponding analogues exhibit is not due 
to an osmotic change in the media. 
3.3. Influence of 3-deoxy.-o-galactose on hepatocyte GAG 
synthesis 
The synthetic derivative 3-deoxy-D-galactose was tested 
for its effects on GAG synthesis at concentrations of l, 10 
and 20 mM. There was no significant effect on GAG 
synthesis at a concentration of 1 raM. An inhibitory effect 
was, however, evident at a concentration of 10 raM, at 
which point the incorporation of [3H]glucosamine and 
35SO4 were, respectively, 77% and 72% of control (Fig. 
5A). At the highest concentration, 20 mM 3-deoxy-o- 
galactose, the incorporation decreased further to, respec- 
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Fig. 5. Effects o f  increasing concentrat ions o f  3-deoxy-D-galactose on 
cel lu lar  GAG and total protein synthesis. Cultures were incubated as in 
Fig. 3 but in the absence (control) or presence of 1, 10 and 20 mM 
3-deoxy-D-galactose. The radioactivity incorporated into cell GAGs, or 
protein, are illustrated in panels A and B, respectively. The values 
represent the mean_  S.D. of triplicate cultures. Statistical analyses using 
a paired t-test revealed that in panel A, control vs. 1 mM, not significant; 
control vs. 10 raM, P _< 0.01; control vs. 20 raM, P _< 0.01. In panel B, 
control vs. 1 mM, P_<0.01; control vs. 10 mM or 20 raM, not signifi- 
cant. 
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Fig. 4. Effect of increasing concentration of glucuronate on hepatocyte 
cellular GAG and total protein synthesis. Hepatocyte cultures were 
incubated with [3H]glucosamine/35504, or [3H]leucine, for 24 h in the 
absence (control) or presence of glucuronate at 1.0, 10 and 20 mM. The 
radioactivity incorporated into cell GAGs (A), or protein (B), was 
determined. The values represent the mean + S.D. of triplicate analyses. 
tively, 60% and 58% with respect to the control (Fig. 5A). 
The effect of 3-deoxy-D-galactose on total cell protein 
synthesis is demonstrated in Fig. 5B. At a concentration of 
1 mM there was a consistent unexplained increase in the 
incorporation of [3H]leucine to 130% of that seen in the 
control. At concentrations of 10 and 20 raM, however, 
3-deoxy-D-galactose had no inhibitory effect on protein 
synthesis (Fig. 5B). 
3.4. Influence of compound 10 on hepatocyte GAG synthe- 
sis 
The synthetic derivative 10 was tested for its effects on 
hepatocyte GAG synthesis at concentrations of l, 5, 10 
and 20 mM. There was no significant effect on GAG 
synthesis at a concentration of 1 mM. An inhibitory effect 
was, however, evident at a concentration of 5 mM and 
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Fig. 6. Effects of increasing concentrations of compound I0 on cellular 
GAG and total protein synthesis. Hepatocyte cultures were incubated with 
[3H]glucosamine/35SO4, or [3H]leucine, for 24 h in the absence (con- 
trol) or presence of compound 10 at 1.0, 5.0, 10 and 20 mM. The 
radioactivity incorporated into cell GAGs (A) or protein (B) was deter- 
mined. The values are mean_S.D, of triplicate analyses. Statistical 
analyses: in panel A, control vs. 1.0 mM, not significant; control vs. 5.0 
raM, not significant; control vs. 10 mM, P < 0.01; control vs. 20 mM, 
P < 0.01. In panel B, control vs. 1.0 raM, not significant; control vs. 5.0 
raM, not significant; control vs. 10 mM, P < 0.01; control vs. 20 mM, 
P < 0.01. 
became more pronounced with increasing concentrations 
(Fig. 6A). The residual hepatocyte GAG synthetic poten- 
tial was approx. 35% and 10% of the control at 10 and 20 
raM, respectively. A similar inhibitory effect of compound 
10 was seen on total cell protein synthesis (Fig. 6B). 
3.5. Effect of  uridine on compound lO-induced inhibition 
of  GAG and protein synthesis 
The add i t ion  o f  ur id ine  at 0.1 and 1.0 mM to cu l tures  
conta in ing  compound 10 at 10 and 20 mM did  not  lead to 
any recovery  o f  the incorporat ion  o f  GAG precursors  into 
GAGs  (data not  shown) .  However ,  ur id ine at 0.1 mM did  
reverse  part ia l ly  the inh ib i tory  e f fect  o f  compound 10 on 
prote in  synthes is .  Moreover ,  at 10 mM 10, 1 mM ur id ine  
increased  prote in  synthes is  by  41% over  the non-ur id ine  
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Fig. 7. Effect of uridine on the compound 10-dependent inhibition of 
protein synthesis. Hepatocyte cultures were incubated with [3H]leucine 
for 24 h in the presence or absence of 1 mM uridine, and with compound 
10 at 10 and 20 mM. The amount of [3H]leucine incorporated into 
proteins was determined. The values represent the mean + S.D. of tripli- 
cate analyses. The control values were obtained by culturing cells in the 
absence of uridine or compound 1O. Statistical analyses: control vs. 10 
rnM, P < 0.01; control vs. 20 mM, P < 0.01; 10 mM vs. 10 mM + uridine, 
P < 0.01; 20 mM vs. 20 mM+ uridine, P < 0.01. 
treated counterparts, whereas, at 20 mM 10, 1 mM uridine 
increased protein synthesis by 115% (Fig. 7). Thus, in the 
presence of compound 10 the addition of uridine caused an 
increase in protein synthesis but no change in GAG syn- 
thesis when compared to treatment of the cells with the 
monosaccharide rivative alone. 
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Fig. 8. A Sephacryl S-300 elution profile of [3H]glucosamine and 3s SO4_ 
labelled GAGs from the hepatocyte cellular fraction. Hepatocyte GAGs 
were labelled and isolated as described in Section 2. The isolated GAGs 
consisted of 92-95% heparan sulphate as measured by nitrous acid 
sensitivity. An aliquot of the isolated GAGs containing 6.104 d.p.m. 3H 
and 2.5.104 d.p.m. 35S was applied to a Sephacryl S-300 column 
(0.7× 100 cm) and eluted with 4 M guanidine-HCl, 0.05 M sodium 
acetate, 0.5% CHAPS pH 6.0. Fractions of 0.58 ml were collected at a 
flow rate of 4.3 ml/min. The distribution of 3H and the 3~S counts are 
shown by the (closed) and (open) circles, respectively. V 0 corresponds to
fraction 21 as determined by the elution of Blue dextran. V~ corresponds 
to fraction 60 as determined by the elution of 35SO 4. Peak B is a tritium 
but not sulphate-labelled peak, whereas Peak C is a sulphate but not 
tritium-labelled component, 
3.6. Size of GAG chains synthesized in the presence and 
absence of 3-deoxy-D-galactose 
A 
Doubly labelled GAGs isolated from the cells of either 
control cultures, or those treated with 20 mM 3-deoxy-D- 
galactose, were chromatographed on Sephacryl S-300 as 
described in the Materials and Methods Section. Examples 
of the eluted labelled GAG profiles from control cultures 
are shown in Fig. 8. It is apparent that there are two major 
peaks which have been labelled with [3H]glucosamine. 
These have been marked A and B. Peak A is also labelled 
with 35SO4 whereas peak B is not. Peak C represents a 
small sulphate-labelled molecule which was not labelled 
with tritium. The elution positions and labelling of peaks B 
and C were not affected by 3-deoxy-D-galactose as seen in 
Fig. 9A and 9B. Attention was therefore directed primarily 
to peak A. 
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Fig. 9. A Sephacryl S-300 elution profile of hepatocyte cellular GAGs 
synthesized in the presence of 3-deoxy-D-galactose. Hepatocyte GAGs 
were synthesized and labelled in the presence of 20 mM 3-deoxy-D- 
galactose as described in Section 2. Following isolation they were 
chromatographed as in Fig. 8. Panel A illustrates the [3H]glucosamine- 
labelled GAGs in the presence (open circles) and absence (closed circles) 
of 3-deoxy-o-galactose. Panel B illustrates the corresponding data with 
labelled sulphate. Note that the peak corresponding to A in Fig. 8 is 
significantly retarded when synthesized in the presence ofthe analogue of
D-galactose, whereas those corresponding to B and C are not affected. 
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Fig. 10. Elution profile of hepatocyte c llular GAGs produced in the 
absence and presence ofcompound 10. A similar profile was seen in the 
presence ofuridine. Hepatocyte cultures were incubated with [3H]gluco- 
samine and 35SO4 for 24 h in the presence or absence of 20 mM 
compound 10. The radiolabelled cellular GAGs were isolated and an 
aliquot was applied to a Sephacryl S-300 column. The [3H]glucosamine 
(panel A) and 35SO 4(panel B) elution profiles incorporated into hepato- 
cyte GAGs are shown, respectively, in the absence (closed circles) or 
presence (open circles) of compound 10. Note that he peak correspond- 
ing to A in Fig. 8 is significantly reduced and retarded inthe presence of
compound 10 whereas those corresponding to B and C are not affected. 
As demonstrated in Fig. 9A the GAGs isolated from 
3-deoxy-D-galactose tr ated cultures were significantly re- 
tarded on Sephacryl-S 300 chromotography when com- 
pared to GAGs isolated from control cultures. The 35S 
chromatographic profile, demonstrated in Fig, 9B, con- 
firmed that seen with [3H]glucosamine. The elution posi- 
tion corresponds to a molecule of approx. 17 kDa (Kav = 
0.44), whereas the material obtained from the control 
cultures eluted at a position corresponding to a molecular 
mass of 66 kDa (Kay = 0.26). 
3.7. Size of GAG chains synthesized in the presence and 
absence of compound 10, and the effect of uridine 
Doubly labelled GAGs isolated from the cells of either 
control cultures, those treated with 20 mM compound 10, 
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or those treated with 20 mM compound 10 and 1 mM 
uridine, were chromatographed on Sephacryl S-300. Ex- 
amples of the elution profiles of the labelled glycosamino- 
glycan are shown in Figs. 8 and 10, respectively. As with 
3-deoxy-o-galactose, theelution positions and labelling of 
peaks B and C were not affected by compound 10. How- 
ever, the GAGs isolated from compound 10-treated cul- 
tures (peak A) were significantly retarded on Sephacryl 
S-300 when compared to GAGs isolated from control 
cultures. The corresponding 3SS chromatographic profiles 
are demonstrated in Figs. 8 and 10. The results with 35S04 
incorporation confirm those seen with [3H]glucosamine. 
The retarded peak is significantly smaller than that seen in 
the controls. The elution position corresponds toa molecule 
of approx. 30 kDa (Kay =0.36), whereas the material 
obtained from the control cultures eluted in a position 
corresponding to a molecular mass of 66 kDa. Although 
uridine partially reversed the effect of compound 10 on 
protein synthesis (Fig. 7), it had no effect on GAG synthe- 
sis nor did it increase the size of the GAG chains made 
(FigsFig. 10A and 10B). 
4. Discussion 
4.1. 3-Deoxy-D-galactose 
The purpose of the present study was to synthesize 
monosaccharide rivatives which, on the basis of their 
structure, should interfere with the synthesis of GAGs such 
as heparan sulphate. Ideally these prepared compounds 
should have an effect on GAG synthesis but not affect 
protein synthesis. This dichotomy in effect would show a 
more specific action of the monosaccharide rivatives. 
3-Deoxy-D-galactose proved to be such a compound. This 
compound was shown to interfere with hepatocyte GAG 
synthesis, did not affect protein synthesis, and the GAGs 
were significantly shorter than those obtained from un- 
treated cells. Although not yet investigated, and for rea- 
sons outlined below, it is highly likely that this derivative 
interferes with the synthesis of several different GAGs. 
This suggestion is based, in part, on the fact that the 
linkage region found in heparan sulphate between the 
GAG and the core protein is also found in other GAGs 
[381. 
Metabolic studies with labelled 3-deoxy-o-galactose 
have yet to be performed. The metabolic utilization of 
3-deoxy-D-galactose in cells is therefore still open to spec- 
ulation. It is highly likely, however, that 3-deoxy-D-galac- 
tose undergoes metabolic activation in much the same way 
as does D-galactose proper [39]. This process involves the 
utilization of ATP and the conversion of D-galactose (or 
3-deoxy-D-galactose) into the active metabolite D-galac- 
tose-l-PO 4 (3-deoxy-D-galactose-l-PO4), following which 
it is converted into UDP-galactose (UDP-3-deoxy-~ 
galactose). This metabolic activation takes place at C-l, 
and there is no apparent theoretical reason why the activa- 
tion should be affected by the removal of the hydroxyl 
group at C-3. 
It is anticipated that the presence of UDP-3-deoxy-D- 
galactose would either lead to 1) the incorporation of the 
D-galactose analogue into the growing GAG chain in the 
linkage region, or 2) serve as an analogue of UDP-galac- 
tose inhibiting the incorporation of I>galactose itself into 
this same linkage region. In either case there should be an 
inhibition of GAG chain elongation as observed experi- 
mentally. 
Alternative routes of metabolic intervention in GAG 
chain elongation are also possible. UDP-Galactose nor- 
mally may undergo epimerization atC-4 and be converted 
into UDP-glucose. UDP-Glucose may then be converted 
metabolically into UDP-glucuronic acid which in turn can 
then be decarboxylated to provide UDP-xylose [40]. A 
similar event is possible with the UDP-galactose analogue. 
There is no apparent theoretical objection why the removal 
of the hydroxyl at C-3 should influence or prevent epimer- 
ization at C-4. Metabolically generated 3-deoxy derivatives 
of D-glucuronic acid and D-xylose are therefore possible. 
These two latter activated sugars might have effects on the 
incorporation of o-xylose in the serine-carbohydrate link- 
age region, or on the incorporation of D-glucuronic acid in 
either the linkage region or the remainder of the GAG 
chain itself. Both of these events may be responsible for 
the significantly shortened GAG chain length obtained 
from the hepatocytes treated with 3-deoxy-D-galactose. 
An additional possibility which must be considered is
an effect of the galactose analogue on GAG chain degrada- 
tion either during or shortly after synthesis. Experiments 
are planned to explore this possibility. 
The degree of inhibition of sulphate incorporation i all 
cases paralleled the degree of inhibition of [3H]gluco- 
samine, suggesting that 3-deoxy-D-galactose was not influ- 
encing sulphation of nascent glycosaminoglycan chains in 
the treated cultures. 
The various metabolic fates of 3-deoxy-o-galactose dis-
cussed above are now being explored. 
4.2. Methyl (methyl 4-chloro-4-deoxy-[3-o-galactopyrano- 
sid)uronate (Compound 10) 
In addition to 3-deoxy-D-galactose a novel monosaccha- 
ride derivative was synthesized, which, on the basis of its 
structure, should interfere with the synthesis of GAGs such 
as heparan sulphate. The agent prepared, compound 10, 
proved to have such inhibitory properties, as measured by 
[3H]glucosamine and 35804 incorporation into 
hepatocyte-synthesized GAGs. Furthermore, the GAGs 
produced were, with respect to molecular mass, 50% 
smaller than that produced by untreated cells. Compound 
10 also had an effect on hepatocyte protein synthesis 
which was partially reversed by uridine, however, uridine 
did not reverse the inhibition of GAG synthesis by com- 
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pound 10. Thus, part of compound 10's effect on GAG 
synthesis is not mediated through its inhibitory effect on 
protein synthesis. 
The rationale for using uridine to improve protein syn- 
thesis in the presence of compound 10 stems from observa- 
tions with D-galactosamine. This latter sugar is known to 
perturb hepatocyte protein synthesis through its rapid acti- 
vation into a UDP-metabolite using cellular UTP. During 
this process galactosamine sequesters uridine and in so 
doing depletes the cellular UTP pool [41]. This latter effect 
is in turn responsible for the inhibition of protein synthesis 
[41]. 
Since compound 10 decreased both GAG and protein 
synthesis the observed inhibition of GAG synthesis could 
have been due to one of two broad metabolic mechanisms. 
The monosaccharide rivative, if it were perceived as a 
galactose or glucose analogue, could undergo metabolic 
activation to a UDP-metabolite depleting the hepatocyte 
uridine nucleotide pool, and secondarily causing a general 
decrease in protein synthesis. This result in turn would 
have led to an inhibition of the GAG synthesis, since the 
proteoglycan core protein would no longer be available as 
a site for GAG chain initiation. 
Alternatively, compound 10, as a D-glucuronic acid 
analogue, could interfere with the incorporation of sugar 
precursors from natural intermediates, uch as UDP- 
glucuronic acid, into nascent GAG chains. As an indepen- 
dent metabolic event compound 10 may sequester a signif- 
icant proportion of the uridine nucleotide pool. The latter 
would then lead to a decrease in protein synthesis, thereby 
aggravating the inhibition of GAG synthesis. 
In an attempt to alleviate the potential UTP deficiency, 
and see whether the inhibition of protein synthesis played 
any role in the observed inhibition of GAG synthesis, 
uridine was added to the cultures at several different 
concentrations ranging from 0.1 /zM to 1.0 raM. In the 
presence of compound 10, uridine at these concentrations 
did not have any significant stimulatory effect on the 
incorporation of [3H]glucosamine and 35SO4 into GAGs 
(data not shown). Partial reversal of the protein synthesis 
effect of compound 10 was seen at the uridine concentra- 
tions cited above. However, complete reversal of the effect 
of compound 10 on protein synthesis with uridine was not 
accomplished even with higher concentrations than those 
reported in the Results Section. Thus, compound 10, in 
addition to affecting GAG synthesis, indeed has other 
metabolic effects, undefined at present, which do impinge 
on the protein synthetic pathway. Nevertheless, the fact 
that GAG synthesis remained inhibited even following 
improvements in protein synthesis indicates that the ana- 
logue does have a more direct, but as yet uncharacterized, 
effect on GAG synthesis. 
The mechanism of the action of compound 10 with 
regard to GAG synthesis is open to speculation, but is 
clearly dependent upon gaining intracellular access. A 
molecule related in structure to compound 10, and which 
lacked the methoxyl group at C-l, namely sodium 4-de- 
oxy-D-xylo-hexopyranuronate, w s not effective as an in- 
hibitor of hepatocyte GAG synthesis (data not shown). The 
hydrophillic properties of compound 10 might be suffi- 
ciently reduced by the methoxyl group at C-1 as well as by 
the ester function to allow its penetration into the cell, 
following which there are several possible routes for its 
metabolism. 
One metabolic pathway has already been alluded to 
above, namely the potential activation of compound 10 
utilizing UTP. It is not clear whether the methoxyl group 
at C-I would interfere with this process. Acidic glycosi- 
dases, which are abundant in cellular lysosomes, can po- 
tentially remove the methoxyl group at C-1 to permit an 
eventual reaction with UTP. In either of these cases the 
glycosyl moiety of compound 10 could be incorporated 
into a growing GAG chain. In so doing it is likely to 
interfere with subsequent chain elongation because of the 
absence of a hydroxyl group at C-4. However, animals 
unlike plants lack the necessary enzymes to convert glu- 
curonate into a UDP-sugar [42,43], and thus UTP activa- 
tion of the analogue is unlikely, unless compound 10 is 
perceived metabolically as a galactose or glucose ana- 
logue. 
Alternatively, compound 10 may be partially metabo- 
lized through the glucuronate pathway, entering the pen- 
tose phosphate cycle and subsequently yielding an ana- 
logue of glucose [44]. In this way the modification at C-4 
may be introduced into any of the carbohydrate moieties 
which serve as GAG precursors. A further alternative 
involves compound 10 acting as a competitor of UDP- 
glucuronate and thereby interfering with UDP-glucuronyl 
transferase activity. Such a role could be attributed to 
compound 10 based on the similarity of its structure to that 
of glucuronate. This possibility may depend on the hydrol- 
ysis of the methyl ester function at C-6, a process which 
could be readily accomplished by intracellular esterases. 
Both of these latter two scenarios would account for the 
inhibition of GAG synthesis and shortening of the newly 
synthesized chains. Again compound 10, as with 3-deoxy- 
D-galactose, may also have affected a GAG degradative 
pathway. 
Thus, a novel monosaccharide rivative (compound 
10) has been shown to inhibit hepatocyte GAG (heparan 
sulphate) synthesis, producing GAG chains which are about 
half of the normal size. Several possible mechanisms by 
which this effect may occur have been discussed, and are 
now the subject of further investigation. 
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